Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy. PMID: 32150489 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report (...) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other

2020 EvidenceUpdates

2. Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer

Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

3. Archimedes for biopsy of suspected lung cancer

navigation systems. Archimedes for biopsy of suspected lung cancer (MIB211) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 10Current care pathway Current care pathway People with known or suspected lung cancer should be offered a contrast-enhanced chest CT scan to diagnosis and stage the disease. They should also be offered endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for biopsy (...) of paratracheal and peri-bronchial intra- parenchymal lung lesions. When taking samples, the healthcare professional should ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of predictive markers. The following publications have been identified as relevant to this care pathway: • NICE's guideline on lung cancer: diagnosis and management • NICE's quality standard on lung cancer in adults • NICE's interventional

2020 National Institute for Health and Clinical Excellence - Advice

4. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

2020 EvidenceUpdates

5. Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. (Abstract)

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced (...) of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment.Among patients

2020 NEJM

6. eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations

eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment (...) cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001

2020 European Society for Medical Oncology

7. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 212 2 Information about lorlatinib Information about lorlatinib Marketing authorisation indication Marketing authorisation indication 2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non- small cell lung cancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK (...) that there was a significant unmet need for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), even though 4 ALK tyrosine kinase inhibitor (TKI) treatments are available. The committee noted that neither crizotinib nor ceritinib are preferred for untreated disease since the availability of alectinib. Brigatinib has been approved for previously treated disease only after crizotinib. If alectinib's treatment effect wanes the only current option is chemotherapy. ALK TKI treatments

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Evidence Report for Investigating symptoms of lung cancer: a guide for all health professionals

, which can hinder early diagnosis and treatment. 4, 5 Lung cancer presentations can also be complex, due to co-morbidities or plausible alternative diagnoses. 6 Lung cancer symptoms can present in a similar manner to other conditions such as chronic obstructive pulmonary disease (COPD), chronic heart failure and coronary heart disease. 7 Therefore, it is important to increase awareness of lung cancer symptoms and risk factors, and to provide all health professionals with the most recent evidence (...) with symptoms or signs consistent with lung cancer. The Guide does not provide advice on the following: • adults with mesothelioma • adults with lung metastases arising from primary cancer originating outside the lung • children (younger than 18 years) with lung cancer • adults with rare lung tumours • adults with benign lung tumours, and • adults being screened for lung cancer. For more information on the potential role of screening for asymptomatic patients, visit Cancer Australia’s lung cancer screening

2020 Cancer Australia

9. Investigating symptoms of lung cancer: a guide for all health professionals

The association of lung cancer with smoking can lead to lung cancer patients feeling stigmatised, contributing to delays in help-seeking for symptoms 4,5 and psychological distress. 6 Risk factors for lung cancer Lifestyle factors - current or former tobacco smoking Environmental or occupational factors - passive smoking - occupational exposures e.g. radon, asbestos, diesel exhaust, silica - air pollution Personal factors - increasing age - family history of lung cancer - chronic lung disease e.g. chronic (...) obstructive pulmonary disease (COPD), pulmonary fibrosis - personal history of cancer e.g. lung cancer, head and neck cancer, bladder cancer Symptoms and signs of lung cancer Symptoms can present in a similar manner to other conditions such as COPD, chronic heart failure and coronary heart disease. 7 Please refer to the flow chart overleaf for symptoms and signs of lung cancer, recommended investigations and referrals, and timeframes for referral. 80 90 100 70 60 50 40 30 20 10 Stage at diagnosis and 5

2020 Cancer Australia

10. Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer

and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials April 2019, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to May 16, 2019 Search Strategy: # Searches 1 exp lung neoplasms/ or exp lung cancer/ 2 (((lung or thorax or thoracic or pulmonary) adj3 (cancer$ or neoplasm$ or carcinom$ or malignan$ or tumo?r$ or adenocarcinoma$)) or NSCLC).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, ui, sy, sh, tx, ct] 3 1 or 2 4 exp (...) , P.M. Ellis, R. Goffin, W. Hanna, D. Maziak, A. Swaminath, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: April 27, 2020 This document describes the OH (CCO)-Lung Cancer Disease Site Group endorsement of the recommendations for the treatment of patients with clinical stage III N2 non-small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available at www.nice.org.uk/guidance/ng122. The recommendations were also endorsed

2020 Cancer Care Ontario

11. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report

screening, defer surveillance imaging of lung nodules, and minimize nonurgent interventions during the evaluation of lung nodules and stage I non-small cell lung cancer. INTERPRETATION: There was consensus that during the COVID-19 pandemic, it is appro- priatetodeferenrollmentinlungcancerscreeningandmodifytheevaluationoflungnodules ABBREVIATIONS: CDC = Centers for Disease Control and Prevention; COVID-19 = coronavirus disease 19; Lung-RADS = Lung CT Screening Reporting and Data System; pCA = probability (...) : consensus statement; COVID-19; lung cancer screening; lung nodule In some parts of the world, the coronavirus disease 2019 (COVID-19) pandemic has stressed the health- care systems close to or even past their breaking point. Rightfully, much of the attention to date has focused on the immediate needs of patients suffering from the disease, particularly those who are critically ill. The strain on health-care systems and the need to control the virus using containment (testing and isolating cases

2020 American College of Chest Physicians

12. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study

of China. 15 Cliniche Humanitas Gavazzeni, Bergamo, Italy. 16 Merck & Co, Kenilworth, NJ. 17 The Netherlands Cancer Institute, Amsterdam, the Netherlands. PMID: 32078391 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report (...) Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

13. Radiation Therapy for Small Cell Lung Cancer

irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med . 1999 ; 341 : 476–484 | | | In ES disease, treatment typically involves chemotherapy alone x 9 Green, R.A., Humphrey, E., Close, H., and Patno, M.E. Alkylating agents in bronchogenic carcinoma. Am J Med . 1969 ; 46 : 516–525 | | | with or without PCI. x 10 Slotman, B., Faivre-Finn, C., Kramer, G. et al. Prophylactic cranial irradiation in extensive small (...) will commission a replacement or reaffirmation within 5-years of publication. 1. Introduction Small cell lung cancer (SCLC) is the second most common thoracic malignancy, representing approximately 13% of newly diagnosed lung cancers. x 1 in: N. Howlader, A. Noone, M. Krapcho, (Eds.) SEER Cancer Statistics Review . National Cancer Institute , Bethesda, MD ; 1975-2016 ( Available at: ) . ( Accessed November 22, 2019 ) SCLC is a particularly aggressive malignancy, with only about one-third of patients diagnosed

2020 American Society for Radiation Oncology

14. Lung cancer and mesothelioma service guidance during the COVID-19 pandemic

When indicated, use PET-CT prior to any staging EBUS and to identify alternative biopsy target. o In cases where there is a low risk of mediastinal disease, consider percutaneous lung biopsy or proceeding directly to treatment based on lung cancer probability (including the use of the Herder model) ? Omit contrast enhanced CT brain in clinical stage II lung cancer. ? Do not perform full lung function testing when the clinician and surgeon are happy with simple spirometry. ? Do not perform (...) chemotherapy for patients with mesothelioma to those with epithelioid tumours. 4. Information for Patients Please discuss with all patients undergoing diagnostic and staging tests or being referred for treatment that there are intense pressures on the NHS which may result in longer waits to undergo tests, see specialist clinicians and commence treatment. Please ensure they have contact details of their lung cancer specialist nurses (LCNS) or relevant team to discuss any concerns and seek support

2020 British Thoracic Society

15. ASTRO/ESTRO Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic Full Text available with Trip Pro

ASTRO/ESTRO Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement - ScienceDirect JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page. COVID-19 campus closures: to subscribed content Share Export Available online 6 April 2020 Practice recommendations for lung cancer radiotherapy during the COVID-19 (...) pandemic: An ESTRO-ASTRO consensus statement Author links open overlay panel … Show more Under a Creative Commons open access Highlights • Risk-mitigation pandemic scenario: efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. • Postponement or interruption of radiotherapy of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection

2020 American Society for Radiation Oncology

16. CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

2020 Cardiovascular and Interventional Radiological Society of Europe

17. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules

EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lung cancer. It helps early detection of lung cancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lung cancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lung cancer recommends sputum cytology for investigation in people with suspected lung cancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided

2020 National Institute for Health and Clinical Excellence - Advice

18. Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

Create file Cancel Actions Cite Share Permalink Copy Page navigation J Thorac Cardiovasc Surg Actions . 2019 Nov 23;S0022-5223(19)33106-X. doi: 10.1016/j.jtcvs.2019.09.193. Online ahead of print. Assessment of Preoperative Noninvasive Ventilation Before Lung Cancer Surgery: The preOVNI Randomized Controlled Study , , , , , , , Collaborators, Affiliations Expand Collaborators GFPC Group : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Respiratory Disease Unit, HIA (...) Respiratory Disease Unit, HIA Sainte Anne, Toulon, France. PMID: 31924365 DOI: Item in Clipboard Assessment of Preoperative Noninvasive Ventilation Before Lung Cancer Surgery: The preOVNI Randomized Controlled Study Nicolas Paleiron et al. J Thorac Cardiovasc Surg . 2019 . Show details J Thorac Cardiovasc Surg Actions . 2019 Nov 23;S0022-5223(19)33106-X. doi: 10.1016/j.jtcvs.2019.09.193. Online ahead of print. Authors , , , , , , , Collaborators GFPC Group

2020 EvidenceUpdates

19. Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer

: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lung cancer. However, nonsmokers with lung cancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lung cancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest

2020 Health Quality Ontario

20. Lorlatinib (Lorviqua) - non-small cell lung cancer (NSCLC)

(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib

2020 Scottish Medicines Consortium